Breaking News, Financial News

Financial Report: InterMune

Esbriet revenue up 204%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InterMune 4Q Revenues: $8.2 million (earnings were $2.7 million in 4Q11) 4Q Loss: $58.6 million (loss of $44.5 million in 4Q11) FY Revenues: $26.2 million (earnings were $5.4 million FY11) FY Loss: $150.1 million (loss of $154.8 million FY11) Comments: Esbriet (pirfenidone) revenue in the quarter was $8.2 million, up 204%. Results in the quarter included the effect of the approximate 11% German price decrease of Esbriet, which became effective September 15, 2012. Esbriet was approved in Can...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters